Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00810160 · ClinicalTrials.gov registry record · Phase 1
The Impact of Oligosaccharides and Bifidobacteria on the Intestinal Microflora of Premature Infants
A Phase 1 study of Fecal Microflora in the Formula Fed Premature Infant, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT00810160 is a Phase 1 study of Fecal Microflora in the Formula Fed Premature Infant that has completed, run by University of California, Davis. The registered enrollment target is 59 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00810160, a Phase 1 study of Fecal Microflora in the Formula Fed Premature Infant, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see whether dietary supplements can change the germs in the intestines of premature infants to be more like those of healthy breast fed term babies.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT ProlactPlus
- DIETARY_SUPPLEMENT GOS galacto-oligosaccharides
- DIETARY_SUPPLEMENT Bifidobacterium infantis
- DIETARY_SUPPLEMENT Bifidobacterium animalis
Study Locations (1)
California
- UC Davis Medical Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2009-06 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00810160
The ClinicalTrials.gov registry entry for NCT00810160 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fecal Microflora in the Formula Fed Premature Infant appearing as the primary indexed condition, and to 4 interventions - of which ProlactPlus is the first listed.
NCT00810160 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00810160 about?
NCT00810160 is a clinical study titled "The Impact of Oligosaccharides and Bifidobacteria on the Intestinal Microflora of Premature Infants". The purpose of this study is to see whether dietary supplements can change the germs in the intestines of premature infants to be more like those of healthy breast fed term babies.
What is the current status of trial NCT00810160?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2009-06. Estimated completion is 2015-11.
What conditions does trial NCT00810160 study?
This clinical trial studies the following conditions: Fecal Microflora in the Formula Fed Premature Infant.
What interventions are being tested in trial NCT00810160?
The interventions under investigation include: ProlactPlus (DIETARY_SUPPLEMENT), GOS galacto-oligosaccharides (DIETARY_SUPPLEMENT), Bifidobacterium infantis (DIETARY_SUPPLEMENT), Bifidobacterium animalis (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00810160?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00810160 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.